Free Trial
NASDAQ:IART

Integra LifeSciences (IART) Stock Price, News & Analysis

Integra LifeSciences logo
$22.70 -0.18 (-0.79%)
(As of 02:20 PM ET)

About Integra LifeSciences Stock (NASDAQ:IART)

Key Stats

Today's Range
$22.58
$22.97
50-Day Range
$16.95
$26.70
52-Week Range
$16.81
$45.42
Volume
241,922 shs
Average Volume
1.10 million shs
Market Capitalization
$1.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00
Consensus Rating
Reduce

Company Overview

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Integra LifeSciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
60th Percentile Overall Score

IART MarketRank™: 

Integra LifeSciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 496th out of 965 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Integra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on 1 buy rating, 4 hold ratings, and 3 sell ratings.

  • Amount of Analyst Coverage

    Integra LifeSciences has only been the subject of 4 research reports in the past 90 days.

  • Read more about Integra LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Integra LifeSciences are expected to grow by 1.63% in the coming year, from $2.45 to $2.49 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Integra LifeSciences is -252.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Integra LifeSciences is -252.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Integra LifeSciences has a PEG Ratio of 0.78. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Integra LifeSciences has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Integra LifeSciences' valuation and earnings.
  • Percentage of Shares Shorted

    8.00% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently increased by 1.37%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Integra LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Integra LifeSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.00% of the float of Integra LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Integra LifeSciences has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Integra LifeSciences has recently increased by 1.37%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Integra LifeSciences has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Integra LifeSciences this week, compared to 4 articles on an average week.
  • Search Interest

    5 people have searched for IART on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Integra LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.10% of the stock of Integra LifeSciences is held by insiders.

  • Percentage Held by Institutions

    84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Integra LifeSciences' insider trading history.
Receive IART Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

IART Stock News Headlines

Integra Lifesciences names Mojdeh Poul as CEO
Donald Trump can’t save you from this crisis
Elon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force will put millions of Americans out of work. The ripple effects could nudge the US economy into a catastrophic tailspin. If this happens, you need to be prepared. That’s why a former Trump advisor is sharing his contingency plan with the public. What is Musk talking about?
Morgan Stanley Remains a Sell on Integra Lifesciences (IART)
Integra LifeSciences Announces Q3 2024 Financial Results
See More Headlines

IART Stock Analysis - Frequently Asked Questions

Integra LifeSciences' stock was trading at $43.55 at the beginning of 2024. Since then, IART shares have decreased by 47.7% and is now trading at $22.76.
View the best growth stocks for 2024 here
.

Integra LifeSciences Holdings Co. (NASDAQ:IART) issued its quarterly earnings results on Monday, November, 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.02. The company's revenue was down .4% on a year-over-year basis.

Integra LifeSciences shares split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were payable to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences subsidiaries include ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and more.

Integra LifeSciences' top institutional investors include Sachem Head Capital Management LP (3.15%), Geode Capital Management LLC (2.36%), Charles Schwab Investment Management Inc. (1.22%) and Glenmede Trust Co. NA (0.94%). Insiders that own company stock include Stuart Essig, Glenn Coleman, Raymond G Murphy, Michael J Mcbreen, Lisa Evoli, Witte Jan De, Jeffrey Mosebrook and Tru St Partnership, LP.
View institutional ownership trends
.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD).

Company Calendar

Last Earnings
11/04/2024
Today
11/18/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IART
CUSIP
45798520
Employees
3,946
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$24.00
High Stock Price Target
$35.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+5.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
8 Analysts

Profitability

Net Income
$67.74 million
Pretax Margin
-0.76%

Debt

Sales & Book Value

Annual Sales
$1.54 billion
Cash Flow
$4.82 per share
Book Value
$19.72 per share

Miscellaneous

Free Float
74,772,000
Market Cap
$1.76 billion
Optionable
Optionable
Beta
1.08

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:IART) was last updated on 11/18/2024 by MarketBeat.com Staff
From Our Partners